✦ LIBER ✦

Treatment of chronic hepatitis B

✍ Scribed by Gary L. Davis

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 365 KB
Volume: 14
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.1840140325

No coin nor oath required. For personal study only.

✦ Synopsis

Treatment of Chronic Hepatitis B Chronic HBV infection is common and affects more than 200 million individuals worldwide. It is estimated that more than 1 million persons in the United States alone are Chronically infected with this virus. Fur-

📜 SIMILAR VOLUMES

Lamivudine treatment of chronic hepatiti

Lamivudine treatment of chronic hepatitis B

✍ Geoffrey Dusheiko 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

Thymic factor X treatment of chronic hep

Thymic factor X treatment of chronic hepatitis B

✍ Janusz Cianciara; Tomasz Laskus 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

We read with interest the report of Mutchnick et al. 1 I on the effectiveness of thymosin therapy for chronic hepatitis B. Both in this paper and in the accompanying editorial (2), the authors cite the study by Dabrowslu et al. (31, which described the ability of thymic factor X (TFX), an extract of

Advances in the treatment of chronic hep

Advances in the treatment of chronic hepatitis B virus infection

✍ Adriana R. Marques; Stephen E. Straus 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 2 views

Recent advances in our understanding of the replicative mechanism of HBV, and the development of potent nucleoside analogues as clinically effective inhibitors of the HIV reverse transcriptase or herpesvirus polymerases has opened a new era in the treatment of chronic HBV infection. Single agent the

Double-blind, randomized controlled tria

Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B

✍ Artillo, Santiago; Pastore, Giuseppe; Alberti, Alfredo; Milella, Michelle; Santa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 1 views

Pilot studies have demonstrated that recombinant interleukin 2 (rIL-2) has an indirect antiviral activity against hepatitis B virus, but the minimal dose of rIL-2 for induction of this effect was not defined. The aim of the study was to ascertain the most efficient dose of rIL-2 for induction of the

Serum 2′,5′-oligoadenylate synthetase ac

Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B

✍ Michiko Shindo; Tadao Okuno; Masayuki Matsumoto; Makoto Takeda; Tatsuro Takino; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

A pilot study of 2′,3′-dideoxyinosine fo

A pilot study of 2′,3′-dideoxyinosine for the treatment of chronic hepatitis B

✍ Michael W. Fried; Julia C. Korenman; Adrian M. Di Bisceglie; Yoon Park; Jeanne G 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 1 views

The nucleoside analog 2',3'-dideoxyinosine, currently being used to treat patients infected with the human immunodeficiency virus, has been shown to inhibit viral replication in certain cell culture systems of hepatitis B virus and the duck model of chronic hepatitis B infection. We studied the effe